PFIZER INC (PFE.DE) Stock Price & Overview
FRA:PFE • US7170811035
Current stock price
The current stock price of PFE.DE is 24.74 EUR. Today PFE.DE is up by 1.77%. In the past month the price increased by 8.3%. In the past year, price increased by 15.99%.
PFE.DE Key Statistics
- Market Cap
- 140.73B
- P/E
- 8.84
- Fwd P/E
- 9.55
- EPS (TTM)
- 2.80
- Dividend Yield
- 6.36%
PFE.DE Stock Performance
PFE.DE Stock Chart
PFE.DE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE is one of the better performing stocks in the market, outperforming 75.2% of all stocks.
PFE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. PFE.DE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
PFE.DE Earnings
On February 3, 2026 PFE.DE reported an EPS of 0.66 and a revenue of 17.56B. The company beat EPS expectations (14.29% surprise) and beat revenue expectations (2.56% surprise).
PFE.DE Forecast & Estimates
35 analysts have analysed PFE.DE and the average price target is 24.89 EUR. This implies a price increase of 0.6% is expected in the next year compared to the current price of 24.74.
For the next year, analysts expect an EPS growth of -7.56% and a revenue growth -1.3% for PFE.DE
PFE.DE Groups
Sector & Classification
PFE.DE Financial Highlights
Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.8. The EPS increased by 3.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.42% | ||
| ROA | 3.73% | ||
| ROE | 8.99% | ||
| Debt/Equity | 0.71 |
PFE.DE Ownership
PFE.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.77 | 200.017B | ||
| SAN | SANOFI | 9.74 | 199.437B | ||
| SNW | SANOFI | 9.73 | 199.316B | ||
| UCB | UCB SA | 25.72 | 51.448B | ||
| UNC | UCB SA | 25.39 | 50.806B | ||
| MRK | MERCK KGAA | 13.28 | 47.739B | ||
| 1BAYN | BAYER AG-REG | 8.59 | 39.493B | ||
| BAYN | BAYER AG-REG | 8.48 | 38.997B | ||
| IPN | IPSEN | 13.73 | 14.038B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 17.45 | 10.457B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.77B | ||
| VIRP | VIRBAC SA | 16.3 | 2.945B | ||
| DMP | DERMAPHARM HOLDING SE | 18.77 | 2.544B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PFE.DE
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Company Info
IPO: 1944-01-17
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 75000
Phone: 13026587581
PFIZER INC / PFE.DE FAQ
What does PFIZER INC do?
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Can you provide the latest stock price for PFIZER INC?
The current stock price of PFE.DE is 24.74 EUR. The price increased by 1.77% in the last trading session.
What is the dividend status of PFIZER INC?
PFIZER INC (PFE.DE) has a dividend yield of 6.36%. The yearly dividend amount is currently 1.49.
What is the ChartMill rating of PFIZER INC stock?
PFE.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is PFIZER INC (PFE.DE) expected to grow?
The Revenue of PFIZER INC (PFE.DE) is expected to decline by -1.3% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for PFIZER INC?
PFIZER INC (PFE.DE) has a market capitalization of 140.73B EUR. This makes PFE.DE a Large Cap stock.
What is the ownership structure of PFIZER INC (PFE.DE)?
You can find the ownership structure of PFIZER INC (PFE.DE) on the Ownership tab.